Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MFA-370 in Metastatic Urothelial Cancer
NCT05390645Phase 2Withdrawn
- Sponsor
- Ectin Research AB
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibuprofen, ivermectin in urothelial carcinoma (UC), sponsored by Ectin Research AB. Planned start Dec 2024; status: withdrawn.
02
Drugs
ibuprofenivermectin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05390645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390645.